132 related articles for article (PubMed ID: 6400064)
1. Effects of biochemical modulation of drug combinations directed at the ribonucleotide reductase site on leukemia L1210 cell growth in culture.
Sato A; Carter GL; Bacon PE; Cory JG
Adv Enzyme Regul; 1983; 21():259-70. PubMed ID: 6400064
[TBL] [Abstract][Full Text] [Related]
2. Effects of combinations of drugs having different modes of action at the ribonucleotide reductase site on growth of L1210 cells in culture.
Sato A; Carter GL; Bacon PE; Cory JG
Cancer Res; 1982 Nov; 42(11):4353-7. PubMed ID: 6751522
[TBL] [Abstract][Full Text] [Related]
3. The utility of combinations of drugs directed at specific sites of the same target enzyme--ribonucleotide reductase as the model.
Cory JG; Sato A; Carter GL; Bacon PE; Montgomery JA; Brown NC
Adv Enzyme Regul; 1985; 23():181-92. PubMed ID: 3907303
[TBL] [Abstract][Full Text] [Related]
4. Effect of ribonucleotide reductase inhibitors on the growth of human colon carcinoma HT-29 cells in culture.
Matsumoto M; Tihan T; Cory JG
Cancer Chemother Pharmacol; 1990; 26(5):323-9. PubMed ID: 2208572
[TBL] [Abstract][Full Text] [Related]
5. Effects of N-hydroxy-N'-aminoguanidine isoquinoline in combination with other inhibitors of ribonucleotide reductase on L1210 cells.
Weckbecker G; Weckbecker A; Lien EJ; Cory JG
J Natl Cancer Inst; 1988 Jun; 80(7):491-6. PubMed ID: 2452889
[TBL] [Abstract][Full Text] [Related]
6. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells.
Carter GL; Cory JG
Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392
[TBL] [Abstract][Full Text] [Related]
7. Selective resistance of L1210 cell lines to inhibitors directed at the subunits of ribonucleotide reductase.
Carter GL; Cory JG
Adv Enzyme Regul; 1989; 29():123-39. PubMed ID: 2699151
[TBL] [Abstract][Full Text] [Related]
8. Studies on the differential mechanisms of inhibition of ribonucleotide reductase by specific inhibitors of the non-heme iron subunit.
Sato A; Bacon PE; Cory JG
Adv Enzyme Regul; 1984; 22():231-41. PubMed ID: 6089512
[TBL] [Abstract][Full Text] [Related]
9. Synergistic inhibition of leukemia L1210 cell growth in vitro by combinations of 2-fluoroadenine nucleosides and hydroxyurea or 2,3-dihydro-1H-pyrazole[2,3-a]imidazole.
Sato A; Montgomery JA; Cory JG
Cancer Res; 1984 Aug; 44(8):3286-90. PubMed ID: 6611198
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of drug resistance to inhibitors directed at the individual subunits of ribonucleotide reductase.
Carter GL; Thompson DP; Cory JG
Cancer Commun; 1989; 1(1):13-20. PubMed ID: 2701080
[TBL] [Abstract][Full Text] [Related]
11. Antineoplastic effect of the combination of 2,3-dihydro-1H-pyrazole[2,3a]imidazole plus deoxyadenosine/erythro-9-(2-hydroxyl-3-nonyl)adenine in mice with L1210 leukemia cells.
Matsumoto M; Weckbecker G; Cory JG
Cancer Commun; 1990; 2(1):1-6. PubMed ID: 2369548
[TBL] [Abstract][Full Text] [Related]
12. 2'-Deoxy-2'-methylene derivatives of adenosine, guanosine, tubercidin, cytidine and uridine as inhibitors of L1210 cell growth in culture.
Cory AH; Samano V; Robins MJ; Cory JG
Biochem Pharmacol; 1994 Jan; 47(2):365-71. PubMed ID: 8304981
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of combinations of drugs that inhibit Ehrlich tumor cell ribonucleotide reductase.
Sato A; Cory JG
Cancer Res; 1981 May; 41(5):1637-41. PubMed ID: 6783298
[TBL] [Abstract][Full Text] [Related]
14. Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors.
Cory JG; Carter GL
Cancer Res; 1988 Feb; 48(4):839-43. PubMed ID: 3276399
[TBL] [Abstract][Full Text] [Related]
15. Ribonucleotide reductase activity and growth of glutathione-depleted mouse leukemia L1210 cells in vitro.
Weckbecker G; Cory JG
Cancer Lett; 1988 Jun; 40(3):257-64. PubMed ID: 3289734
[TBL] [Abstract][Full Text] [Related]
16. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.
Finch RA; Liu M; Grill SP; Rose WC; Loomis R; Vasquez KM; Cheng Y; Sartorelli AC
Biochem Pharmacol; 2000 Apr; 59(8):983-91. PubMed ID: 10692563
[TBL] [Abstract][Full Text] [Related]
17. Drug action on ribonucleotide reductase.
Cory JG; Carter GL
Adv Enzyme Regul; 1985; 24():385-401. PubMed ID: 3915189
[TBL] [Abstract][Full Text] [Related]
18. Ribonucleotide reductase as a chemotherapeutic target.
Cory JG
Adv Enzyme Regul; 1988; 27():437-55. PubMed ID: 3074632
[TBL] [Abstract][Full Text] [Related]
19. Factors affecting the mRNA levels for the non-heme iron and effector-binding subunits of ribonucleotide reductase.
Carter GL; Cory JG
Adv Enzyme Regul; 1992; 32():227-40. PubMed ID: 1496919
[TBL] [Abstract][Full Text] [Related]
20. Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime.
Tihan T; Elford HL; Cory JG
Adv Enzyme Regul; 1991; 31():71-83. PubMed ID: 1877400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
